A novel Phase 2 double-blind, randomized, controlled clinical trial to evaluate the efficacy of centrally acting, non-toxic ACE inhibition in cognitive impairment associated with SLE

First posted July, 2020, Updated November, 2021; Recruiting
CATEGORIES: CNS Lupus

This research study is being done to test the effects of centrally-acting ACE inhibitor, named lisinopril, on resting metabolism in the brain and on cognitive function. The investigators will see if Lisinopril will decrease resting metabolism in the brain and improve cognitive function (memory and concentration) compared to a non-centrally acting ACE inhibitor called benazepril.

To Learn More Contact
Contact: Andrew Shaw at 516-562-2591 or anshaw@northwell.edu
ClinicalTrials.gov identifier: NCT04486118

The study is sponsored by Northwell Health in collaboration with the Lupus Research Alliance.